drugset / Trial / NCT01881828

Metformin Therapy for Overweight Adolescents With Type 1 Diabetes

NCT01881828 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the proposed research is to evaluate the efficacy and safety of the use of metformin in addition to standard insulin therapy in overweight and obese children and adolescents, age 12-\<20 years, with type 1 diabetes for at least 1 year. Secondary objectives are to assess the effect of metformin on C-peptide levels, a measure of how much insulin is still being produced by the beta cells of the pancreas, and on vascular dysfunction. In addition, an ancillary study is planned to assess if metformin will improve tissue-specific insulin resistance in type 1 diabetes using a hyperinsulinemic euglycemic clamp.

Timeline

Start
2013-09
Primary completion
2014-09
Completion
2014-12

Outcome

Missed primary endpoint

paper However, this differential effect was not sustained at 26-week follow up when mean change in HbA1c from baseline was 0.2% in each group PMID 26624824 ↗

paper the addition of metformin to insulin did not improve glycemic control after 6 months. PMID 26624824 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 2000 mg Oral